Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELC |
---|---|---|
09:32 ET | 1500 | 14.26 |
09:38 ET | 5100 | 14.51 |
09:41 ET | 500 | 14.565 |
09:43 ET | 1350 | 14.75 |
09:45 ET | 100 | 14.6856 |
09:48 ET | 1346 | 14.95 |
09:54 ET | 1955 | 14.88 |
09:56 ET | 100 | 14.77 |
09:57 ET | 200 | 14.67 |
10:01 ET | 100 | 14.6 |
10:03 ET | 100 | 14.575 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celcuity Inc | 554.7M | -5.3x | --- |
Third Harmonic Bio Inc | 555.7M | -16.7x | --- |
Instil Bio Inc | 549.7M | -3.8x | --- |
Altimmune Inc | 560.0M | -3.9x | --- |
Neurogene Inc | 545.1M | -8.4x | --- |
Q32 Bio Inc | 556.6M | -2.9x | --- |
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $554.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 37.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-2.74 |
Book Value | $5.48 |
P/E Ratio | -5.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.